4. Lee JJ, Moon HS, Lee TY, Hwang HS, Ahn MH, Ryu JS. PCR for diagnosis of male
Trichomonas vaginalis infection with chronic prostatitis and urethritis. Korean J Parasitol 2012;50:157-159
https://doi.org/10.3347/kjp.2012.50.2.157
5. Mitteregger D, Aberle SW, Makristathis A, Walochnik J, Brozek W, Marberger M, Kramer G. High detection rate of
Trichomonas vaginalis in benign hyperplastic prostatic tissue. Med Microbiol Immunol 2012;201:113-116
https://doi.org/10.1007/s00430-011-0205-2
6. Gardner WA Jr, Culberson DE, Bennett BD.
Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med 1986;110:430-432.
7. Sutcliffe S, Neace C, Magnuson NS, Reeves R, Alderete JF. Trichomonosis, a common curable STI, and prostate carcinogenesis - a proposed molecular mechanism. PLoS Pathog; 2012. 8e1002801
https://doi.org/10.1371/journal.ppat.1002801
8. Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, Platz EA, Sutcliffe S, Fall K, Kurth T, Ma J, Stampfer MJ, Mucci LA. Prospective study of
Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians’ Health Study. J Natl Cancer Inst 2009;101:1406-1411
https://doi.org/10.1093/jnci/djp306
9. Sutcliffe S, Giovannucci E, Alderete JF, Chang T, Gaydos CA, Zenilman JM, De Marzo AM, Willett WC, Platz EA. Plasma antibodies against
Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:939-945
https://doi.org/10.1158/1055-9965.EPI-05-0781
11. Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 2014;38:329-338
https://doi.org/10.1016/j.canep.2014.06.002
12. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology 2002;16:217-226.
13. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology 2011;25:400-410.
14. Ha NH, Park DG, Woo BH, Kim DJ, Choi JI, Park BS, Kim YD, Lee JH, Park HT.
Porphyromonas gingivalis increases the invasiveness of oral cancer cells by upregulating IL-8 and MMPs. Cytokine 2016;86:64-72
https://doi.org/10.1016/j.cyto.2016.07.013
15. Simons BW, Durham NM, Bruno TC, Grosso JF, Schaeffer AJ, Ross AE, Hurley PJ, Berman DM, Drake CG, Thumbikat P, Schaeffer EM. A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. J Pathol 2015;235:478-489
https://doi.org/10.1002/path.4472
16. Xu Y, Li H, Chen W, Yao X, Xing Y, Wang X, Zhong J, Meng G.
Mycoplasma hyorhinis activates the NLRP3 inflammasome and promotes migration and invasiveness of gastric cancer cells. PLoS One 2013;8:e77955
https://doi.org/10.1371/journal.pone.0077955
17. Twu O, Dessi D, Vu A, Mercer F, Stevens GC, de Miguel N, Rappelli P, Cocco AR, Clubb RT, Fiori PL, Johnson PJ.
Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses. Proc Natl Acad Sci USA 2014;111:8179-8184
https://doi.org/10.1073/pnas.1321884111
19. Chung HY, Kim JH, Han IH, Ryu JS. Polarization of M2 macrophages by interaction between prostate cancer cells treated with
Trichomonas vaginalis and adipocytes. Korean J Parasitol 2020;58:217-227
https://doi.org/10.3347/kjp.2020.58.3.217
20. Kim JH, Kim SS, Han IH, Sim S, Ahn MH, Ryu JS. Proliferation of prostate stromal cell induced by benign prostatic hyperplasia epithelial cell stimulated with
Trichomonas vaginalis via crosstalk with mast cell. Prostate 2016;76:1431-1444
https://doi.org/10.1002/pros.23227
21. Han IH, Kim JH, Kim SS, Ahn MH, Ryu JS. Signalling pathways associated with IL-6 production and epithelial-mesenchymal transition induction in prostate epithelial cells stimulated with
Trichomonas vaginalis. Parasite Immunol 2016;38:678-687
https://doi.org/10.1111/pim.12357
22. Kim JH, Han IH, Shin SJ, Park SY, Chung HY, Ryu JS. Signaling role of adipocyte leptin in prostate cell proliferation induced by
Trichomonas vaginalis. Korean J Parasitol 2021;59:235-249
https://doi.org/10.3347/kjp.2021.59.3.235
23. Somers KD, Brown RR, Holterman DA, Yousefieh N, Glass WF, Wright GL jr, Schellhammer PF, Qian J, Ciavarra RP. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer 2003;107:773-780
https://doi.org/10.1002/ijc.11464
24. Jang SM, Han H, Jun YJ, Jang SH, Min KW, Sim J, Ahn HI, Lee KH, Jang KS, Paik SS. Clinicopathological significance of CADM4 expression, and its correlation with expression of E-cadherin and Ki-67 in colorectal adenocarcinomas. J Clin Pathol 2012;65:902-906
https://doi.org/10.1136/jclinpath-2012-200730
25. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer DM. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-615
https://doi.org/10.1016/S1470-2045(12)70137-7
30. Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008;54:1379-1384
https://doi.org/10.1016/j.eururo.2007.11.026
33. Rao SR, Snaith AE, D Marino D, Cheng X, Lwin ST, Orriss IR, Hamdy FC, Edwards CM. Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. Br J Cancer 2017;116:227-236
https://doi.org/10.1038/bjc.2016.402
35. Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasiveness in gastric cancer. Ann Oncol 2011;22:2267-2276
https://doi.org/10.1093/annonc/mdq739
37. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002;72:9-18.
38. Miyake M, Lawton A, Goodison S, Urquidi V, Rosser CJ. Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer. Pathol Res Pract 2014;210:74-78
https://doi.org/10.1016/j.prp.2013.08.013
39. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. CCR2 expression correlates with prostate cancer progression. J Cell Biochem 2007;101:676-685
https://doi.org/10.1002/jcb.21220
40. Lu Y, Chen Q, Corey E, Xie W, Fan J, Mizokami A, Zhang J. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 2009;26:161-169
https://doi.org/10.1007/s10585-008-9226-7
44. Kruk J, Aboul-Enein HY. Reactive Oxygen and Nitrogen Species in carcinogenesis: implications of oxidative stress on the progression and development of several cancer types. Mini Rev Med Chem 2017;17:904-919
https://doi.org/10.2174/1389557517666170228115324
45. Fusté NP, Castelblanco E, Felip I, Santacana M, Fernandes-Hernanadez R, Gatius S, Pedraza N, Pallares J, Cemeli T, Valls J, Rarres M, Ferrezuelo F, Dolcet X, Matias-Guiu X, Gari E. Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer. Oncotarget 2016;7:26979-26991
https://doi.org/10.18632/oncotarget.8876
46. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993;7:331-342
https://doi.org/10.1101/gad.7.3.331
47. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, Dye C, Yang J, Dai M, Zhang X, Li A, Burbelo P, Stanley ER, Pestell RG. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 2006;26:4240-4256
https://doi.org/10.1128/MCB.02124-05
48. Lo UG, Lee CF, Lee MS, Hsieh JT. The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. Int J Mol Sci 2017;18:2079
https://doi.org/10.3390/ijms18102079